Prosecution Insights
Last updated: November 04, 2026

Chinook Therapeutics Canada Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Chinook Therapeutics Canada Inc. is currently navigating the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This prosecution effort involves 1 distinct examiner and 1 distinct art unit, which reflects a concentrated approach to its current patent filings. Such a focused profile suggests that the company's current activity is limited to a single technical inquiry within the patent office. For practitioners, the presence of 1 distinct art unit indicates that the prosecution is confined to a specific administrative group, potentially streamlining the management of the application.

The busiest examiner, BAUER, NICOLA MARIA, is assigned 1 busiest examiner pending office action. Since the total number of pending office actions is 1, this examiner is the sole point of contact for the company's active matters. The alignment between 1 distinct examiner and the total workload indicates a streamlined prosecution path where no other examiners are currently involved. Practitioners can conclude that the 1 busiest examiner pending office action is the primary driver of the current portfolio status, requiring focused attention on this single individual's review process.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BAUER, NICOLA MARIA 1 57.8% +53.1%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17925126 SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF BAUER, NICOLA MARIA —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17925126 SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF BAUER, NICOLA MARIA —

Top Art Units

Art UnitApps
1621 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17925126 SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF BAUER, NICOLA MARIA 1621 §102§103 Final Rejection — Pending Nov 14, 2022

Managing Chinook Therapeutics Canada Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Chinook Therapeutics Canada Inc. have?

Chinook Therapeutics Canada Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Chinook Therapeutics Canada Inc. applications?

Nicola Maria Bauer has the most, with 1 of Chinook Therapeutics Canada Inc.'s pending office actions.

What technology area are Chinook Therapeutics Canada Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month